

Glenmark launches anesthesia reversing agent sugammadex in US

Sugammadex is used by anesthesiologists to reverse the effects of certain muscle relaxants (neuromuscular blocking agents such as rocuronium or vecuronium) given during general anesthesia.



Mumbai: Glenmark Pharmaceuticals' US-arm announced the commercial launch of sugammadex injection single dose vials in the US.

The drug is a therapeutically equivalent version of Merck's (MSD in India) Bridion, which recorded estimated sales of \$1.6 billion over the 12-month period ending May this year, according to IQVIA.

Sugammadex is used by anesthesiologists to reverse the effects of certain muscle relaxants (neuromuscular blocking agents such as rocuronium or vecuronium) given during general anesthesia.

“Achieving a Day 1 launch reflects the agility, and execution discipline behind our injectable strategy. It also underscores our ability to identify meaningful market opportunities across the US healthcare system,” said Marc Kikuchi, President and Business Head, North America, Glenmark.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/glenmark-launches-anesthesia-reversing-agent-sugammadex-in-us/132704871>

